Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
Ayalew Tefferi, Hassan B. Alkhateeb, Naseema Gangat
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 23

Showing 23 citing articles:

2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management
Haris Ali, Andrea Bacigalupo
American Journal of Hematology (2024) Vol. 99, Iss. 5, pp. 938-945
Closed Access | Times Cited: 10
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
Ayalew Tefferi, Animesh Pardanani
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
Claire Harrison, Ruben A. Mesa, Moshe Talpaz, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 10, pp. e729-e740
Closed Access | Times Cited: 6
Chronic Neutrophilic Leukemia: Advances in Diagnosis, Genetic Insights, and Management Strategies
Ismail Elbaz Younes, Paweł Mróz, Mehrnoosh Tashakori, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 227-227
Open Access
Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1‐Positive and ‐Negative Myeloproliferative Neoplasms
Tariq I. Mughal, John O. Mascarenhas, Raajit K. Rampal, et al.
Hematological Oncology (2025) Vol. 43, Iss. 1
Closed Access
Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes
Sarah Wall, Roni Tamari, Zachariah DeFilipp, et al.
Annals of Hematology (2025)
Open Access
DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications
Paola Barone, Adele Bottaro, Rossana Leanza, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 4, pp. 227-227
Open Access
Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation
Hiroyuki Takamori, Ying‐Jung Huang, Hidehito Fukushima, et al.
Leukemia (2025)
Closed Access
Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
Kristin Holl, Nicolas Chatain, S. Krapp, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm
Stéphane de Botton, Christian Récher, Jorge E. Cortés, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 2
Assessment of Total Antioxidant Capacity, 8-Hydroxy-2′-Deoxy-Guanosine, the Genetic Landscape, and Their Associations in BCR::ABL-1-Negative Chronic and Blast Phase Myeloproliferative Neoplasms
Mihnea‐Alexandru Găman, Cristina Mambet, Ana Iulia Neagu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6652-6652
Open Access | Times Cited: 1
Национальные клинические рекомендации по диагностике и лечению Ph-негативных миелопролиферативных новообразований (истинной полицитемии, эссенциальной тромбоцитемии, первичного миелофиброза) (редакция 2024 г.)
Анаит Левоновна Меликян, Irina N. Subortseva, А. М. Ковригина, et al.
Clinical oncohematology (2024) Vol. 17, Iss. 3, pp. 291-334
Open Access | Times Cited: 1
Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors
Tiziano Barbui, Arianna Ghirardi, Alessandra Carobbio, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Leukemic conversion involving RAS mutations of type 1 CALR-mutated primary myelofibrosis in a patient treated for HCV cirrhosis: a case report
Petruta Gurban, Cristina Mambet, Anca Botezatu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage
Edwin Uriel Suárez, Miguel Á. Piris, Socorro María Rodríguez‐Pinilla, et al.
Annals of Hematology (2024) Vol. 103, Iss. 5, pp. 1797-1799
Closed Access
Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?
Ayalew Tefferi, Tiziano Barbui
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1450-1453
Closed Access
Optimizing Outcomes of Accelerated and Blast-Phase Myeloproliferative Neoplasms
Naseema Gangat, Ayalew Tefferi
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, pp. S92-S94
Closed Access
When and how to transplant in myelofibrosis – recent trends
Naman Sharma, Giuseppe Gaetano Loscocco, Naseema Gangat, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-19
Closed Access
Morphological, clinical, and molecular profiling of post-polycythemia vera accelerated/blast phase occurring with and without antecedent secondary myelofibrosis
Laura Pelagatti, Giulia Pozzi, Samuele Cortellazzi, et al.
Frontiers in Hematology (2024) Vol. 3
Open Access
HMGB1 as a Biomarker for Myeloproliferative Neoplasm Complicated with Atherosclerosis
Lunbi Wu, Dongxue Han, Xiaodong Zhang, et al.
Research Square (Research Square) (2024)
Open Access
Myelodysplastic/Myeloproliferative Neoplasms with Features Intermediate between Primary Myelofibrosis and Chronic Myelomonocytic Leukemia: Case Series and Review of the Entity
Arturo Bonometti, Simone Zanella, Daoud Rahal, et al.
Hemato (2024) Vol. 5, Iss. 3, pp. 230-250
Open Access
Transformation into acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1::RUNX1T1 from JAK2-mutated essential thrombocythemia: a case report
Chie Asou, Tomoyuki Sakamoto, Kodai Suzuki, et al.
Journal of Medical Case Reports (2024) Vol. 18, Iss. 1
Open Access
Transplant Outcomes in Myelofibrosis: Impact of Donor Type [Cord Blood Grafts Supported by CD34+ selected Cells (Haplo-Cord) vs Matched Donors]
Nima Ghalehsari, Franco Castillo Tokumori, Zhengming Chen, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 11, pp. 1100.e1-1100.e11
Closed Access
Clonal evolution: a landmark of MPN evolution
Nabih Maslah, Stéphane Giraudier, Bruno Cassinat, et al.
Frontiers in Hematology (2024) Vol. 3
Open Access
Dominance of mutations in epigenetic regulators and a diversity of signaling alterations in blast‐phase BCR::ABL1‐negative myeloproliferative neoplasms
Petruta Gurban, Cristina Mambet, Anca Botezatu, et al.
American Journal of Hematology (2024)
Open Access
Page 1

Scroll to top